Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - pertactin, pertussis toxoid, poliovirus, inactivated, type, mahoney strain, mef, saukett strain, diphtheria toxoid, filamentous haemagglutinin, fha, tetanus toxoid - suspension for injection in pre-filled syringe - pertactin 8 µg pertussis toxoid 25 µg poliovirus (inactivated) type 1 (mahoney strain) 40 dagu poliovirus (inactivated) type 2 (mef-1 strain) 8 dagu poliovirus (inactivated) type 3 (saukett strain) 32 dagu diphtheria toxoid filamentous haemagglutinin (fha) 25 µg tetanus toxoid - vaccines

Malta - English - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - pertactin, pertussis toxoid, poliovirus, inactivated, type, mahoney strain, mef, saukett strain, diphtheria toxoid, filamentous haemagglutinin, fha, fimbriae types, and, haemophilus influenzae, type b, polysaccharide, polyribosylribitol phosphate, tetanus toxoid - suspension for injection in pre-filled syringe - pertactin 3 µg pertussis toxoid 20 µg poliovirus (inactivated) type 1 (mahoney strain) 40 dagu poliovirus (inactivated) type 2 (mef-1 strain) 8 dagu poliovirus (inactivated) type 3 (saukett strain) 32 dagu diphtheria toxoid filamentous haemagglutinin (fha) 20 µg fimbriae types 2 and 3 5 µg haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 10 µg tetanus toxoid - vaccines

Malta - English - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - yellow fever, virus strain, d - powder and solvent for suspension for injection - yellow fever virus strain 17d 1000 iu - vaccines

European Union - English - EMA (European Medicines Agency)

laboratorios hipra s.a - live ge- tk- double-gene-deleted bovine herpes virus type 1, strain ceddel: 106.3–107.3 ccid50 - immunologicals - cattle - for the active immunisation of cattle from three months of age against bovine herpes virus type 1 (bohv-1) to reduce the clinical signs of infectious bovine rhinotracheitis (ibr) and field virus excretion.onset of immunity: 21 days after completion of the basic vaccination scheme.duration of immunity: 6 months after completion of the basic vaccination scheme

European Union - English - EMA (European Medicines Agency)

mcm vaccine b.v. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens: pertussis toxoid, filamentous haemagglutinin, pertactin, fimbriae types 2 and 3, hepatitis b surface antigen produced in yeast cells, poliovirus (inactivated): type 1 (mahoney), type 2 (mef-1), type 3 (saukett) produced in vero cells/ haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to meningococcal protein. - meningitis, haemophilus; poliomyelitis; tetanus; diphtheria; whooping cough; hepatitis b - vaccines - vaxelis (dtap-hb-ipv-hib) is indicated for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive diseases caused by haemophilus influenzae type b (hib). the use of vaxelis should be in accordance with official recommendations.

Ireland - English - HPRA (Health Products Regulatory Authority)

merial animal health limited - infectious bursal disease virus, attenuated strain s706 - lyophilisate for suspension - . - avian infectious bursal disease virus (gumboro disease) - chickens - immunological - live vaccine

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - live aroa-gene deleted escherichia coli,type o78,ec34195 - unknown - live aroa-gene deleted escherichia coli,type o78,ec34195 vaccine-microbial active 0.0 - active constituent

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml; isoleucine, quantity: 0.355 mg; leucine, quantity: 0.432 mg - injection, powder for - excipient ingredients: lactose; sorbitol; mannitol; threonine; serine; proline; glycine; alanine; valine; methionine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immunocompromised patients with no history of the disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml; isoleucine, quantity: 0.355 mg - injection, powder for - excipient ingredients: lactose; mannitol; sorbitol; threonine; serine; proline; glycine; alanine; valine; methionine; leucine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immunocompromised patients with no history of the disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml - injection, powder for - excipient ingredients: lactose; mannitol; sorbitol; threonine; serine; proline; glycine; alanine; valine; methionine; isoleucine; leucine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immuncompromised patients with no history of the disease.